JuanPabloAlderuccioMD
Hematology • Miami, FLHematologic Oncology
Associate Professor, Lymphoma Program, Division of Hematology, Sylvester Comprehensive Cancer Center
Dr. Alderuccio is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1475 Nw 12th Ave
Miami, FL 33136Phone+1 305-243-6608Fax+1 305-243-4975
Summary
- I am a board-certified Hematologist-Oncologist, and I specialize in the treatment of patients diagnosed with lymphoma. I also conduct clinical research focused on expanding the treatment repertoire for patients diagnosed with various lymphomas.
My research efforts are geared toward improving and expanding the treatment options available for patients diagnosed with both aggressive and indolent lymphomas. In particular, I am interested in the development of novel, targeted therapies which hinges on the use of genetic sequencing technology. My current research is aimed at identifying clinical characteristics in patients with marginal zone lymphoma in an attempt to distinguish those prone to a worse outcome, as well as a higher risk for transformation to an aggressive lymphoma. Furthermore, I am also involved in studies integrating PET/CT data in the risk stratification of lymphoma patients, with the goal of developing strategies for individualize care.
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 2014 - 2017
New York Medical College (Metropolitan)Residency, Internal Medicine, 2011 - 2014
Certifications & Licensure
FL State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Clinical Investigator Career Development Award Lymphoma Research Foundation, 2022
- FDA-AACR Oncology Educational Fellowship FDA and AACR, 2021-2022
- K12 Calabresi Clinical Oncology Research Career Development Award NCI, 2019-2021
Clinical Trials
- Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma Start of enrollment: 2022 Feb 11
Roles: Sponsor-Investigator, Contact, Principal Investigator
Publications & Presentations
PubMed
- Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature.Côme Bommier, Brian K Link, Brianna J Gysbers, Matthew J Maurer, Melissa C Larson
Blood Advances. 2024-12-10 - Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial.Juan Pablo Alderuccio, Alvaro J Alencar, Jonathan H Schatz, Russ A Kuker, Georgios Pongas
The Lancet. Haematology. 2024-12-06 - Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia.Michele D Stanchina, Skye Montoya, Alexey V Danilov, Jorge J Castillo, Alvaro J Alencar
Nature Reviews. Clinical Oncology. 2024-12-01
Abstracts/Posters
- Splenic Marginal Zone Lymphoma: A U.S Population-Based Survival Analysis (1997-2016)Juan Pablo Alderuccio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...Juan Pablo Alderuccio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Juan Pablo Alderuccio, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Omission of Staging Bone Marrow Biopsy Does Not Affect Outcomes in Patients with Stage I Extranodal Marginal Zone Lymphoma (EMZL) Treated with Radiation Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
Sylvester Cancer Tip Sheet for Dec. 2024December 17th, 2024- Zynlonta Pushing into Remission 2 Other Advanced Lymphomas: TrialsDecember 16th, 2024
- Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular LymphomaDecember 8th, 2024
- Join now to see all
Committees
- Member, Protocol Review and Monitoring Committee 2021 - Present
- Member, American Society of Hematology Committee on Educational Affairs
Professional Memberships
- Member
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
